Correction: Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability (Clin Cancer Res (2005) 11 (8431–40) DOI: 10.1158/1078-0432.CCR-05-1085);Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8431-8440

  Zhou, Jianfeng ^a   Gao, Qinglei ^a   Chen, Gang ^a   Huang, Xiaoyuan ^a   Lu, Yunping ^a   Li, Kanyan ^a   Xie, Daxing ^a   Zhuang, Liang ^a   Deng, Jingniu ^a   Ma, Ding ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; E1A PROTEIN; MESSENGER RNA; ONCOLYTIC VIRUS; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; VIRUS GLYCOPROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL VIABILITY; CENTROSOME; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; METASTASIS; MITOSIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR REGRESSION; UTERINE CERVIX CARCINOMA; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 28544447125     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-19-3370     Document Type: Erratum

References (35)

1. Dai W, Cogswell JP. Polo-like kinases and the microtubule organization center: targets for cancer therapies. Prog Cell Cycle Res 2003;5:327-34.
2. Weichert W, Denkert C, Schmidt M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90:815-21.
3. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275-86.
4. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via si RNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005;19:611-3.
5. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005;24:260-6.
6. Van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24: 2844-59.
7. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;19:6660-9.
8. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-312.
9. Khuri FR, Nemunaitis J, Ganly J, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
10. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19:2-12.
11. Heise C, Hermiston C, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
12. Stubdal H, Perin N, Lemmon M, et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 2003; 63:6900-8.
13. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61:8743-50.
14. Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7K/gp19K region. Gene Ther 2001;8:1123-31.
15. Gary K, Boyer J. Isolation, growth, and purification of defective adenovirus deletion mutants. In: Wold WSM, editor. Adenovirus methods and protocols. Totowa (NJ): Humana Press; 1999. p. 25-32.
16. Hermiston TW, Tollefson AE, Wold WSM. Construction of mutations in the adenovirus early region 3 (E3) transcription units. In: Wold WSM, editor. Adenovirus methods and protocols. Totowa (NJ): Humana Press; 1999. p. 11-24.
17. Ma D, Gerard RD, Li XY, et al. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997;90: 2738-46.
18. Zhou J, Gurates B, Yang S, et al. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelialstromal interaction in breast tumors mediated by CCAAT/enhancer binding protein β. Cancer Res 2001;61:2328-34.
19. Xu G, Arregui C, Lilien J, et al. PTP1B modulates the association of β-catenin with N-cadherin through binding to an adjacent and partially overlapping target site. J Biol Chem 2002;277: 49989-97.
20. Gao YS, Chen XP, Li KY, et al. Nude mice model of human hepatocellular carcinoma via orthotopic implantation of histologically intact tissue. World J Gastroenterol 2004;10:3107-11.
21. Von Eschenbach AC. A vision for the national cancer program in the United States. Nat Rev Cancer 2004;4: 820-8.
22. Balagué C, Noya F, Alemany R, et al. Human papillomavirus E6 E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organo-typic cultures of human keratinocytes. J Virol 2001;75: 7602-11.
23. Baron M, Lewis V. Images in clinical medicine. Liver metastases from lung cancer. N Engl J Med 2001; 345:180.
24. Lorenz M, Hochmuth K, Muller HH. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. N Engl J Med 2000;342:1525-6.
25. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
26. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-700.
27. Groot-Wassink T, Aboagye EO, Glaser M, et al. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002;13:1723-35.
28. Fabra A, Parada C, Vinyals A, et al. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts. Gene Ther 2001;8:1627-34.
29. Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001;12:219-26.
30. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20:1562-9.
31. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63: 7497-506.
32. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
33. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-66.
34. Reid T, Galanis E. Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
35. Colin M, Renaut L, Mailly L, et al. Factors involved in the sensitivity of different hematopoietic cell lines to infection by subgroup C adenovirus: implication for gene therapy of human lymphocytic malignancies. Virology 2004;320:23-39.